RITUZENA rituximab (rch) 500 mg/ 50 mL concentrate solution for intravenous infusion 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

rituzena rituximab (rch) 500 mg/ 50 ml concentrate solution for intravenous infusion

celltrion healthcare australia pty ltd - rituximab, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium citrate dihydrate; polysorbate 80; water for injections; sodium chloride - non-hodgkin?s lymphoma rituzena is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia rituzena is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis rituzena (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. rituzena has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic pol

RITUZENA rituximab (rch) 100 mg/ 10 mL concentrate solution for intravenous infusion 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

rituzena rituximab (rch) 100 mg/ 10 ml concentrate solution for intravenous infusion

celltrion healthcare australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: polysorbate 80; water for injections; sodium chloride; sodium citrate dihydrate - non-hodgkin?s lymphoma rituzena is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia rituzena is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis rituzena (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. rituzena has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic pol

BAXTER RINGERS SOLUTION injection 1000mL AHB2304 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

baxter ringers solution injection 1000ml ahb2304

baxter healthcare pty ltd - sodium chloride, quantity: 8.6 g/l; calcium chloride dihydrate, quantity: 330 mg/l; potassium chloride, quantity: 300 mg/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - for restoring the loss of water and electrolytes as required by the clinical condition of the patient.

BAXTER 0.9% SODIUM CHLORIDE INTRAVENOUS INFUSION BP 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

baxter 0.9% sodium chloride intravenous infusion bp

baxter healthcare pty ltd - sodium chloride, quantity: 9 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - baxter sodium chloride 0.9% iv infusion is indicated for extracellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

Mannitol Intravenous Infusion BP 20% w/v Solution for Infusion 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

mannitol intravenous infusion bp 20% w/v solution for infusion

baxter healthcare limited - mannitol - solution for infusion - 20 percent weight/volume - solutions producing osmotic diuresis; mannitol

COMPOUND SODIUM LACTATE (HARTMANN'S SOLUTION) 1000mL injection bag 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

compound sodium lactate (hartmann's solution) 1000ml injection bag

fresenius kabi australia pty ltd - sodium lactate, quantity: 3.17 g/l; sodium chloride, quantity: 6 g/l; potassium chloride, quantity: 0.4 g/l; calcium chloride dihydrate, quantity: 0.27 g/l - injection, intravenous infusion - excipient ingredients: water for injections - compound sodium lactate (hartmann's solution) injection is used for intrvenous fluid and electrolyte replacement, as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency, and as a vehicle for intravenous drug delivery, if the drugs are compatible with the solutions.

COMPOUND SODIUM LACTATE (HARTMANN'S SOLUTION) 500mL injection bag 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

compound sodium lactate (hartmann's solution) 500ml injection bag

fresenius kabi australia pty ltd - sodium lactate, quantity: 3.17 g/l; sodium chloride, quantity: 6 g/l; potassium chloride, quantity: 0.4 g/l; calcium chloride dihydrate, quantity: 0.27 g/l - injection, intravenous infusion - excipient ingredients: water for injections - compound sodium lactate (hartmann's solution) injection is used for intrvenous fluid and electrolyte replacement, as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency, and as a vehicle for intravenous drug delivery, if the drugs are compatible with the solutions.

CSL CMV IMMUNOGLOBULIN VF (human) 1.5 million units/vial injection 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

csl cmv immunoglobulin vf (human) 1.5 million units/vial injection

csl behring australia pty ltd - human immunoglobulin g, quantity: 50 mg/ml; cytomegalovirus immunoglobulin, quantity: 1500000 u - injection, intravenous infusion - excipient ingredients: water for injections; human immunoglobulin a; maltose - cmv immunoglobulin-vf is indicated for the prevention of cmv infection following bone marrow and renal transplants. specifically, the product is indicated when the recipient is seronegative for cmv and receives a graft from a cmv positive donor. cmv immunoglobulin-vf may also be a helpful adjunct to therapy in patients with established cmv infection, e.g. cmv pneumonitis.

Potassium chloride 15% (potassium 20mmol/10ml) solution for infusion 10ml ampoules 英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium chloride 15% (potassium 20mmol/10ml) solution for infusion 10ml ampoules

potassium 20mmol/10ml) solution for infusion 10ml ampoules (hameln pharma ltd - potassium chloride - solution for infusion - 150mg/1ml

Potassium chloride 20% (potassium 13.3mmol/5ml) solution for infusion 5ml ampoules 英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium chloride 20% (potassium 13.3mmol/5ml) solution for infusion 5ml ampoules

potassium 13.3mmol/5ml) solution for infusion 5ml ampoules (hameln pharma ltd - potassium chloride - solution for infusion - 200mg/1ml